- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06064422
Adapting BA for Minimally Verbal Autistic Adults
March 20, 2024 updated by: Vanessa H. Bal, PhD, Rutgers, The State University of New Jersey
Adaptation of a Behavioral Activation Treatment to Treat Depression in Autistic Adults
The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Aim 1.
The first phase of the project will focus on adapting the BeatIt-2 manual to consider specific needs of MV autistic adults.
This procedure includes an intervention development group (IDG), for which MV autistic adults and their supporters (i.e., someone identified as a source of support they can work with) will be recruited.
Aim 2. During the following phase of the project, a feasibility trial will be conducted.
Using the treatment manual and study procedures adapted and refined in phase 1, the trial will examine the feasibility and acceptability of BeatIt-MV.
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vanessa Bal, PhD
- Phone Number: 848-445-9384
- Email: lifespanlab@gsapp.rutgers.edu
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
- Recruiting
- Rutgers University - New Brunswick
-
Contact:
- Vanessa H Bal, PhD
- Phone Number: 848-445-9384
- Email: lifespanlab@gsapp.rutgers.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Minimally verbal
- Aged 18 years or older
- Diagnosis of Autism Spectrum Disorder and clinically significant depression based on clinical best estimate diagnosis using DSM-5 or Diagnostic Manual - Intellectual Disability criteria
- Have a support person willing to participate
- Live in New Jersey or New York, or be within travel distance to Rutgers University
Exclusion Criteria:
- Not able to engage in treatment in English
- current engagement in other treatment for depression
- conditions that may preclude engagement in treatment sessions (e.g., active psychosis, unmanaged seizures)
- high suicide risk (i.e., with a clear plan, expressed intent or recent documented attempts)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BeatIt-MV Treatment Group
Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention.
The support person will complete an initial session before commencement of the 12 weekly sessions.
|
BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2.
The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glasgow Depression Scale for Intellectual Disability (GDS)
Time Frame: Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
The GDS is a 20-item self- and caregiver-reported questionnaire of psychological function over the past week with all items on a "0" (Never/No) to 2 (Always/A lot) scale.
Higher scores equal more distress.
Scores range from 0-32.
The expected change is a decrease in the score.
|
Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
Anxiety Depression and Mood Scale (ADAMS)
Time Frame: Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
The ADAMS is a 20-item caregiver-reported questionnaire of psychological function over the past week with all items on a "0" (Never/No) to 2 (Always/A lot) scale.
Higher scores equal more distress.
Total scores range from 0-84.
The expected change is a decrease in the score.
|
Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
Mood, Interest, & Pleasure Questionnaire (MIPQ)
Time Frame: Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
The MIPQ is a 25-item caregiver-reported questionnaire of behaviors over the past week with all items on a "0" (Never) to 4 (All the time) scale.
Higher scores equal more distress.
Total scores range from 0-100.
The expected change is a decrease in the score.
|
Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vineland Adaptive Behavior Scale, 3rd edition (VABS-3)
Time Frame: Week 1 (initial assessment) to week 22 (follow-up)
|
The VABS-3 is a 381-item caregiver-reported measure of adaptive behavior.
All items in the measure ask the frequency at which the participants performs a behavior, from 0 (never) to 2 (usually).
Scores are age-referenced standard scores.
Domain scores range from 20-140.
Lower scores indicate more lower adaptive behavior.
The expected change is an increase in the score.
|
Week 1 (initial assessment) to week 22 (follow-up)
|
Shalock Quality of Life Questionnaire
Time Frame: Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
The Shalock Quality of Life Questionnaire is a 40-item self- and caregiver-reported measure of quality of life.
Each question prompts the informant to choose one of three options (differing by item) based on which seems most appropriate to them.
Higher scores indicate lower quality of life.
Domain scores range from 10-30.
The expected change is a decrease in score.
|
Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Vanessa Bal, PhD, Rutgers University - New Brunswick
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2023
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
September 25, 2023
First Submitted That Met QC Criteria
September 26, 2023
First Posted (Actual)
October 3, 2023
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro 2021001254
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
Clinical Trials on BeatIt-MV
-
Rutgers, The State University of New JerseyGovernor's Council for Medical Research and Treatment of AutismCompletedDepression | Depressive Symptoms | Autism Spectrum DisorderUnited States
-
Royal Marsden NHS Foundation TrustImperial College London; Institute of Cancer Research, United Kingdom; RM Partners...RecruitingSmoking | Alcoholism | Urologic Diseases | Hypertension | Diabetes | Prostate Cancer | Bladder Cancer | Renal Cancer | Urologic Cancer | Mental Health Issue | Testis CancerUnited Kingdom
-
Daping Hospital and the Research Institute of Surgery...Unknown
-
Fuda Cancer Hospital, GuangzhouCompleted
-
Bandim Health ProjectAarhus University Hospital; Rigshospitalet, DenmarkCompletedMortality | Hospitalization | Adverse EventsGuinea-Bissau
-
Themis Bioscience GmbHCompletedChikungunya Virus InfectionUnited Kingdom
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)CompletedChikungunyaPuerto Rico
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Completed
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health...Active, not recruitingCoronary Artery Disease | Mitral Valve InsufficiencyUnited States, Canada